Doxorubicin/sodium chloride

A quinolinecarboxylic acid derivative with immunosuppressive and anti-neoplastic properties. Inhibits pyrimidine synthesis by blocking the activity of mammalian mitochondrial dihydroorotate dehydrogenase (DHODH: IC50 = 12 nM). Does not affect DHODH

A quinolinecarboxylic acid derivative with immunosuppressive and anti-neoplastic properties. Inhibits pyrimidine synthesis by blocking the activity of mammalian mitochondrial dihydroorotate dehydrogenase (DHODH: IC50 = 12 nM). Does not affect DHODH

A quinolinecarboxylic acid derivative with immunosuppressive and anti-neoplastic properties. Inhibits pyrimidine synthesis by blocking the activity of mammalian mitochondrial dihydroorotate dehydrogenase (DHODH: IC50 = 12 nM). Does not affect DHODH

InformationCADD522 CADD522 is a potent inhibitor of RUNX2(runt-related transcription factor-2)-DNA binding with IC50 of 10 nM. CADD522 exhibits anticancer activity.TargetsRUNX2-DNA (Cell-free assay) 10 nM.

CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active CDK9/cyclin T inhibitor ( IC 50 =11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM: CDK6/cyclinD=145 nM). CDK9-IN-7 shows antitumor activity without

CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active CDK9/cyclin T inhibitor ( IC 50 =11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM: CDK6/cyclinD=145 nM). CDK9-IN-7 shows antitumor activity without

CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active CDK9/cyclin T inhibitor ( IC 50 =11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM: CDK6/cyclinD=145 nM). CDK9-IN-7 shows antitumor activity without

Completely free of dyes and fluoride. Gluten-Free, eliminating the change of allergic reaction to those suffering from Celiac disease or who are gluten intolerant.

Completely free of dyes and fluoride. Gluten-Free, eliminating the change of allergic reaction to those suffering from Celiac disease or who are gluten intolerant.

Product description：Danirixin is a selective, and reversible CXCR2 antagonist, with IC50 of 12.5 nM for CXCL8.

Didodecyl Succinate.

Didodecyl Succinate.